TransMedics Group, Inc. (NASDAQ:TMDX) Receives $144.80 Consensus PT from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been given an average rating of “Buy” by the eleven research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $144.80.

TMDX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Stephens increased their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Robert W. Baird lowered their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Morgan Stanley upped their price objective on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,208 shares of company stock valued at $4,666,565 over the last three months. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently modified their holdings of TMDX. Mutual of America Capital Management LLC acquired a new stake in shares of TransMedics Group during the third quarter worth $784,000. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the period. Natixis Advisors LLC lifted its holdings in shares of TransMedics Group by 29.8% in the third quarter. Natixis Advisors LLC now owns 78,073 shares of the company’s stock valued at $12,258,000 after purchasing an additional 17,933 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of TransMedics Group by 6.5% during the third quarter. Oppenheimer & Co. Inc. now owns 44,893 shares of the company’s stock worth $7,048,000 after buying an additional 2,748 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in shares of TransMedics Group by 11.3% during the third quarter. Victory Capital Management Inc. now owns 4,569 shares of the company’s stock worth $717,000 after buying an additional 464 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $86.35 on Monday. TransMedics Group has a 1-year low of $55.29 and a 1-year high of $177.37. The company has a 50 day moving average of $135.29 and a 200-day moving average of $139.58. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of 91.86 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. On average, equities analysts forecast that TransMedics Group will post 1.08 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.